Neuroendocrine Tumor Treatment Market Size, Share, Growth Insights and Report 2024-2031 | Novartis, AVEO Pharmaceuticals Inc, Eli Lilly & Company

DataM Intelligence has released a new research report on the Neuroendocrine Tumor Treatment market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits, gross margins, and strategic decisions in the global market. The report is enriched with tables, charts, and infographics for a clear presentation of the findings.

Global Neuroendocrine Tumor Treatment Market reached USD 5,053.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 10,398.7 million by 2031. The neuroendocrine tumor treatment market is expected to exhibit a CAGR of 9.7% during the forecast period (2024-2031)

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/neuroendocrine-tumors-treatment-market

Neuroendocrine tumor (NET) treatment involves a comprehensive approach tailored to the individual patient's tumor type, stage, and overall health. Common treatment modalities include surgical resection for localized tumors, medications such as somatostatin analogs to control hormone secretion and targeted therapies like everolimus for advanced NETs. Chemotherapy may be considered for high-grade tumors, while radiation therapy can target specific tumors or metastases. Additionally, peptide receptor radionuclide therapy (PRRT) delivers targeted radiation to NET cells. Treatment plans are developed by a multidisciplinary team to optimize outcomes and effectively manage symptoms, with regular monitoring to assess treatment response and detect recurrence.

List of the Key Players in the Neuroendocrine Tumor Treatment Market: Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. and Sanofi.

Key Developments:

In May 2022, HUTCHMED Limited, a China-based corporation that develops, manufactures, and sells pharmaceutical products, received a Complete Response Letter ("CRL") regarding the New Drug Application ("NDA") from the U.S. Food and Drug Administration for surufatinib indicated for the treatment of pancreatic ("pNETs") and extra-pancreatic (non-pancreatic, "epNETs") neuroendocrine tumors ("NETs").

In November 2022, Lantheus Holdings, Inc., a corporation that develops, manufactures, sells, and distributes diagnostic medical imaging agents and products and POINT Biopharma Global Inc. ("POINT") develops next-generation radiopharmaceuticals for the treatment of cancer formed strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT's PNT2002 and PNT2003 product candidates in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Research Process:

Both primary and secondary data sources have been used in the global Neuroendocrine Tumor Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Neuroendocrine Tumor Treatment Market:

By Therapy Type (Somatostatin analogs (SSAs), Targeted Therapy, Others)

By Indication (Small intestine, Lungs, Pancreas, Gastrointestinal, Others)

By Route of administration (Oral, Parenteral)

By End-user (Hospitals, Clinics, Others)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/neuroendocrine-tumors-treatment-market

Regional Analysis:

➣ North America (US, Canada, Mexico)

➣ Europe (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)

➣ Asia-Pacific (China, India, Japan, Australia, Rest of Asia Pacific)

➣ South America (Brazil, Argentina, Rest of South America)

➣ Middle East and Africa

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Neuroendocrine Tumor Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Neuroendocrine Tumor Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Neuroendocrine Tumor Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Neuroendocrine Tumor Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/neuroendocrine-tumors-treatment-market

The Research Report Offers Answers To The Following Questions:

☛ What is the expected growth rate of the global market for the forecast period?

☛ What are the key driving factors that are responsible to shape the fate of the Neuroendocrine Tumor Treatment market during the forecast period?

☛ What will be the overall size of the market during the analysis period?

☛ What are the prominent market trends which influence the development of the Neuroendocrine Tumor Treatment market across various regions?

☛ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☛ What are the challenges and threats that are likely to act as a barrier to the growth of the Neuroendocrine Tumor Treatment market?

☛ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.